Evaxion achieves preclinical success with AI cancer vaccine
COPENHAGEN - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company with a market capitalization of just under $7 million, has announced preclinical Proof-of-Concept (P...